论文部分内容阅读
目的分析依达拉奉联合尤瑞克林治疗急性脑梗塞的临床疗效。方法选择由我院确诊并收治的126例急性脑梗塞患者作为研究对象,按照数字随机分组的方法将患者分为观察组与对照组,每组各63例,对照组患者在常规治疗基础上给予应用依达拉奉治疗,观察组患者在常规治疗基础上给予依达拉奉联合尤瑞克林治疗,观察两组患者治疗前后的神经功能缺损评分,比较临床疗效。结果两组患者治疗后的NIHSS评分均较治疗前有所减少(P<0.05),观察组患者治疗后的NIHSS评分及治疗总有效率均优于对照组患者(P<0.05)。结论依达拉奉与尤瑞克林联合应用能够进一步提高脑梗塞的治疗效果,可在临床推广使用。
Objective To analyze the clinical efficacy of edaravone combined with noreclin in the treatment of acute cerebral infarction. Methods A total of 126 acute cerebral infarction patients diagnosed and treated in our hospital were selected as research objects. Patients were divided into observation group and control group according to the method of digital randomization. Each group had 63 cases. Patients in control group were given routine treatment The application of edaravone treatment, the observation group patients were treated with edaravone combined with uricocain on the basis of routine treatment. The neurological deficit scores of the two groups before and after treatment were observed and the clinical efficacy was compared. Results The scores of NIHSS after treatment in both groups were significantly lower than those before treatment (P <0.05). The scores of NIHSS and the total effective rate after treatment in the observation group were better than those in the control group (P <0.05). Conclusion The combination of edaravone and uracil can further improve the therapeutic effect of cerebral infarction and can be used in clinical practice.